Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

HIGHLIGHTS

• who: Klara Kropivsek from the (UNIVERSITY) have published the research work: Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma, in the Journal: (JOURNAL) of 27/04/2022
• what: Taken together, the study provides molecular and actionable insights into diverse treatment strategies for patients with MM. MM is a cancer driven by malignant plasma cells (myeloma cells) in the bone marrow (BM)1,2. The authors provide the detailed list of samples used in the analyses in Supplementary Table 10. In the Source Data (to Fig 4c; of which Fig . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.